Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice

Wenjun Ji, Xinlin Chen, Juan Lv, Meng Wang, Shuting Ren, Bing-Xiang Yuan, Bing Wang, Lina ChenInternational Journal of Endocrinology 2014 · DOI

TL;DR

This study investigates how liraglutide, a type 2 diabetes (T2DM) medication, improves skeletal muscle health in diabetic mice. The research reveals that liraglutide protects muscle fibers and mitochondria by modulating key signaling pathways, specifically downregulating PTP1B and upregulating the PI3K/Akt2/GLUT4 pathway, offering a mechanistic explanation for its therapeutic benefits.

What Problem Does This Paper Address?

Type 2 diabetes mellitus (T2DM) is a widespread metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to significant damage in various organs, including skeletal muscle. Skeletal muscle plays a crucial role in glucose uptake and metabolism, and its dysfunction contributes to the overall diabetic state. While liraglutide, a glucagon-like peptide-1 (GLP-1) analog, is an established treatment for T2DM, its precise mechanisms of action, particularly concerning its protective effects on skeletal muscle structure and function, remain incompletely understood. This paper aims to elucidate how liraglutide mitigates skeletal muscle injury and improves metabolic control by examining its impact on specific molecular pathways involved in insulin signaling and cellular integrity.

Methods

The researchers employed a multi-faceted approach to investigate liraglutide's effects:

  • Animal Model: Male KKAy mice, a well-established model for T2DM, were used. These mice were divided into a liraglutide treatment group and a control group. Healthy male C57BL/6J mice served as a normal control.
  • Histological Analysis: Hematoxylin-Eosin (HE) staining was used to examine the general structure of skeletal muscle fibers (myofibrils).
  • Electron Microscopy: This technique was crucial for visualizing the ultrastructure of skeletal muscle, particularly the mitochondria. Researchers quantified mitochondrial number, area, and the ratio of mitochondrial area to overall muscle area.
  • Molecular Analysis:
    • Real-time PCR: Gene expression levels of key players in insulin signaling – protein tyrosine phosphatase 1B (PTP1B), phosphatidylinositol 3-kinase (PI3K), and glucose transporter type 4 (GLUT4) – were measured.
  • Western Blot: Protein levels of PTP1B, PI3K, and importantly, the phosphorylated form of Akt2 (p-Akt2) relative to total Akt2, were assessed. This phosphorylation is a key indicator of pathway activation.

Datasets

Not discussed in the paper. The study utilized experimental data generated from animal models.

Key Insights and Ideas

  • Skeletal Muscle as a Target: The study highlights that liraglutide's benefits extend beyond glucose regulation to directly impact skeletal muscle health, improving both structural integrity (myofibrils) and cellular energy production (mitochondria).
  • Mitochondrial Restoration: A significant finding is the dramatic improvement in mitochondrial health. Liraglutide not only increased the number and size of mitochondria but also improved their internal structure (cristae), suggesting enhanced cellular respiration and energy production in diabetic muscle.
  • PTP1B as a Key Inhibitor: The research strongly implicates PTP1B as a negative regulator of insulin signaling in skeletal muscle. Liraglutide's ability to downregulate PTP1B is presented as a primary mechanism for restoring insulin sensitivity.
  • PI3K/Akt2/GLUT4 Activation: The study demonstrates that liraglutide upregulates the PI3K/Akt2 pathway, leading to increased phosphorylation of Akt2. This activation is directly linked to enhanced expression of GLUT4, the primary glucose transporter in skeletal muscle, facilitating glucose uptake.
  • Synergistic Action: The findings suggest a coordinated action where reduced PTP1B activity and enhanced PI3K/Akt2 signaling work together to improve skeletal muscle function and glucose metabolism in the context of T2DM.

Key Results

  • Mitochondrial Improvement: Liraglutide treatment led to a significant increase in mitochondrial number (+441%), individual mitochondrial area (+113%), and mitochondrial area per unit area (+396%) in the skeletal muscle of KKAy mice.
  • Gene Expression: Liraglutide significantly downregulated PTP1B gene expression while upregulating PI3K and GLUT4 gene expression (P < 0.01).
  • Protein Levels: Western blot analysis confirmed that liraglutide downregulated PTP1B protein levels. Crucially, the ratio of phosphorylated Akt2 (p-Akt2) to total Akt2 was significantly increased (P < 0.01), indicating activation of the PI3K/Akt2 pathway. GLUT4 protein levels were also upregulated.
  • Histological Improvements: HE staining showed improved myofibril structure and reduced vacuolation in liraglutide-treated mice compared to untreated diabetic mice.

Limitations and Future Work

  • Limitations: While the study provides strong mechanistic insights, it was conducted in a mouse model. The direct translation of these findings to human T2DM patients requires further investigation. The study focused on skeletal muscle; exploring liraglutide's effects on other tissues involved in glucose metabolism (e.g., liver, adipose tissue) could provide a more comprehensive picture.
  • Future Work: The authors suggest that further research could explore the precise upstream regulators of PTP1B and PI3K/Akt2 in skeletal muscle and how liraglutide interacts with these. Investigating the long-term effects of liraglutide on skeletal muscle function and its potential to reverse established diabetic muscle pathology would also be valuable. The study's conclusion points to the PTP1B and PI3K/Akt2 signaling pathway as a key target for liraglutide's antidiabetic effects in skeletal muscle, opening avenues for further therapeutic development.

Summary updated

Abstract

Background. Liraglutide (a glucagon-like peptide 1 analog) was used for the treatment of type 2 diabetes (T2DM) which could produce glucose-dependent insulin secretion. Aim. The aim was to investigate whether liraglutide could improve myofibril and mitochondria injury in skeletal muscle and the mechanisms in diabetic KKAy mice. Method. We divided the male KKAy mice into 2 groups: liraglutide group (250 μg/kg/day liraglutide subcutaneous injection) and model group; meanwhile, the male C57BL/6J mice were considered as the control. After 6 weeks, the ultrastructure of skeletal muscle was observed by electron microscope. The gene expressions of protein tyrosine phosphatase 1B (PTP1B), phosphatidylinositol 3-kinase (PI3K), and glucose transporter type 4 (GLUT4) were determined by real-time PCR. The protein levels of the above molecules and phospho-Akt2 (p-Akt2) were measured by Western blot. Results. Liraglutide significantly ameliorated the injury of mitochondria by increasing the number (+441%) and the area (+113%) of mitochondria and mitochondrial area/100 µm(2) (+396%) in skeletal muscle of KKAy mice. The results of real-time PCR and Western blot showed that liraglutide downregulated PTP1B while it upregulated PI3K and GLUT4 (P < 0.01). The protein level of p-Akt2/Akt2 was also increased (P < 0.01). Conclusion. These results revealed that liraglutide could improve myofibril and mitochondria injury in skeletal muscle against T2DM via PTP1B and PI3K/Akt2 signaling pathway.
BibTeX
@article{ji2014liraglutide,
  author = {Wenjun Ji and Xinlin Chen and Juan Lv and Meng Wang and Shuting Ren and Bing-Xiang Yuan and Bing Wang and Lina Chen},
  title = {{Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice}},
  journal = {International Journal of Endocrinology},
  year = {2014},
  doi = {10.1155/2014/312452},
}
Figure